Prostate Specific Membrane Antigen (PSMA)
Showing 51 - 75 of >10,000
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8 Trial in Kansas City
Not yet recruiting
- Stage IIC Prostate Cancer AJCC v8
- +2 more
- Biospecimen Collection
- +9 more
-
Kansas City, KansasUniversity of Kansas Cancer Center
Nov 3, 2023
Prostate Carcinoma Trial in Los Angeles (Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided
Recruiting
- Prostate Carcinoma
- Biopsy of Prostate
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Feb 2, 2022
68Ga-PSMA PET in Diagnosing Metastasis in Ovarian Cancer
Recruiting
- Ovarian Carcinoma
- Gallium Ga 68-labeled PSMA-11
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 12, 2021
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Houston (Computed
Not yet recruiting
- Metastatic Prostate Carcinoma
- +4 more
- Computed Tomography
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Prostate Cancer Trial in Chandigarh (Robotic arm assisted PSMA PET/CT guided prostate biopsy)
Completed
- Prostate Cancer
- Robotic arm assisted PSMA PET/CT guided prostate biopsy
-
Chandigarh, Chandīgarh, IndiaDepartment of Nuclear Medicine, PGIMER
Aug 20, 2021
Thyroid Gland Carcinoma Trial in San Francisco (Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission
Terminated
- Thyroid Gland Carcinoma
- Gallium Ga 68-labeled PSMA-11
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 25, 2021
68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer
Completed
- PET/CT
- +2 more
- total-body PET/CT
-
Shanghai, Shanghai, ChinaShanghai jiaotong University School of Medicine, Renji Hospital
Nov 15, 2021
Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in
Recruiting
- Biochemically Recurrent Prostate Carcinoma
- +6 more
- Computed Tomography
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 7, 2022
Prostate Cancer Trial in San Francisco (CTT1403, CTT1057, 68Ga-PSMA-11)
Active, not recruiting
- Prostate Cancer
- CTT1403
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Apr 14, 2022
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Atlanta
Not yet recruiting
- Castration-Sensitive Prostate Carcinoma
- +2 more
- Abiraterone
- +9 more
-
Atlanta, Georgia
- +1 more
Feb 8, 2023
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma Trial in Palo Alto (Computed Tomography (CT) scan,
Completed
- Prostate Adenocarcinoma
- +2 more
- Computed Tomography (CT) scan
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jan 6, 2022
High Risk Prostate Cancer Trial in Turku (Whole body contrast enhanced computer tomography, 99mTC-HMDP planar bone scintigraphy
Completed
- High Risk Prostate Cancer
- Whole body contrast enhanced computer tomography
- +4 more
-
Turku, FinlandDepartment of Urology
May 3, 2022
PSMA PET/CT for Biochemical Recurrence Detection in Prostate
Completed
- Prostatic Neoplasms
- Recurrence
-
Brest, FranceRichard Pougnet
Jul 29, 2021
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Tumor Trial in Canada, United States (I-131-1095,
Active, not recruiting
- Metastatic Prostate Cancer
- +4 more
-
Duarte, California
- +26 more
Aug 3, 2022
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 Trial
Recruiting
- Advanced Hepatocellular Carcinoma
- +7 more
- Computed Tomography
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Mar 11, 2022
Recurrent Prostate Carcinoma Trial in Los Angeles, San Francisco (other, procedure, radiation)
Active, not recruiting
- Recurrent Prostate Carcinoma
- Best Practice
- +3 more
-
Los Angeles, California
- +1 more
Feb 2, 2022
TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Ga-PSMA PET/CT
-
Brussels, BelgiumInstitut Jules Bordet
Sep 26, 2023
Treatment Trial in Shanghai (Stereotactic Body Radiation Therapy (SBRT))
Recruiting
- Treatment
- Stereotactic Body Radiation Therapy (SBRT)
-
Shanghai, Shanghai, ChinaShanghai Changhai Hospital
Oct 22, 2020
Hepatocellular Carcinoma Trial in Rochester (Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging)
Recruiting
- Hepatocellular Carcinoma
- Computed Tomography
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Mar 22, 2022
[Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
Completed
- Prostate-specific Membrane Antigen Positive Tumors
- +3 more
- [Ga-68]PSMA PET/MR
-
Cleveland, OhioUniversity Hospitals, Case Comprehensive Cancer Center
May 5, 2021
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma Trial in Atlanta
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +3 more
- Computed Tomography
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 9, 2022
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma Trial in Los Angeles
Completed
- Biochemically Recurrent Prostate Carcinoma
- +8 more
- Computed Tomography
- +3 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 29, 2021
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma Trial in Los Angeles (radiation, other, procedure)
Completed
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Gallium Ga 68 Gozetotide
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jun 30, 2021
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in Worldwide (acapatamab, Pembrolizumab, Etanercept)
Active, not recruiting
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- acapatamab
- +3 more
-
Campbell, California
- +29 more
Dec 6, 2022